PF-08046876, a differentiated integrin beta-6 antibody-drug conjugate delivering a potent camptothecin payload optimized for bystander effect and reduced drug efflux

Molecular Cancer Therapeutics · Published 2026-07-28 · DOI 10.1158/1535-7163.mct-25-1509

Free full text

Authors (16)

Rebecca C. Mazahreh, Chuan Bian Lim, Nicolas H. Garcia, Devra J. Olson, Ryan Lyski, Gina M. LoMastro, Andrea Musa, Guadalupe Gutierrez, Samantha M. Sarrett, R. Greg Stacey, Li-Ya Huang, Kelly Hensley, Lori Westendorf, Sohinee Bhattacharyya, Narayana Yeddula, Vivian H. Trang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Mazahreh, R., Lim, C., Garcia, N., et al. (2026). PF-08046876, a differentiated integrin beta-6 antibody-drug conjugate delivering a potent camptothecin payload optimized for bystander effect and reduced drug efflux. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-25-1509

Related articles

• Selected Articles from This Issue · Molecular Cancer Therapeutics · 2026 · Same journal
• RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model · Molecular Cancer Therapeutics · 2026 · Same journal
• HDAC Inhibition Unlocks Tumor Plasticity and Enhances Immunotherapy Response in Myc-Driven Small Cell Lung Cancer · Molecular Cancer Therapeutics · 2026 · Same journal
• Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma · Molecular Cancer Therapeutics · 2026 · Same journal
• Selected Articles from This Issue · Molecular Cancer Therapeutics · 2026 · Same journal
• Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer · Molecular Cancer Therapeutics · 2026 · Same journal
• Mutant-Selective T-cell Receptor Therapy for Solid Tumors · Molecular Cancer Therapeutics · 2026 · Same journal
• Tinengotinib (TT-00420) inhibits tumor growth and overcomes multidrug resistance in gastrointestinal cancers · Molecular Cancer Therapeutics · 2026 · Same journal
• PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer · Molecular Cancer Therapeutics · 2026 · Same journal
• Fedratinib Induces Nonclassical G2–M Arrest via Mitotic Kinase Inhibition and Synergizes with Mitomycin C to Suppress Pancreatic Ductal Adenocarcinoma · Molecular Cancer Therapeutics · 2026 · Same journal